Secondly, a very broad deficiency of the Grx-GSH system was observed in human tumors, including NSCLC, which provides a unique opportunity to target a subset of NSCLC by Trx1 or TrxR1 inhibition. Here, GLRX is linked to non-small cell lung carcinoma.